|
English
|
正體中文
|
简体中文
|
總筆數 :2823024
|
|
造訪人次 :
30273306
線上人數 :
1126
教育部委託研究計畫 計畫執行:國立臺灣大學圖書館
|
|
|
"lanzalone s"的相關文件
顯示項目 1-6 / 6 (共1頁) 1 每頁顯示[10|25|50]項目
臺大學術典藏 |
2021-09-01T01:54:20Z |
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study
|
Faivre S.; Raymond E.; Boucher E.; Douillard J.; Lim H.Y.; Kim J.S.; Zappa M.; Lanzalone S.; Lin X.; DePrimo S.; Harmon C.; Ruiz-Garcia A.; Lechuga M.J.; ANN-LII CHENG |
臺大學術典藏 |
2021-09-01T01:54:07Z |
Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib
|
Harmon C.S.; DePrimo S.E.; Raymond E.; ANN-LII CHENG; Boucher E.; Douillard J.-Y.; Lim H.Y.; Kim J.S.; Lechuga M.J.; Lanzalone S.; Lin X.; Faivre S. |
臺大學術典藏 |
2021-09-01T01:54:07Z |
Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib
|
Faivre S.; Zappa M.; Vilgrain V.; Boucher E.; Douillard J.-Y.; Lim H.Y.; Kim J.S.; Im S.-A.; Kang Y.-K.; Bouattour M.; Dokmak S.; Dreyer C.; Sablin M.-P.; Serrate C.; ANN-LII CHENG; Lanzalone S.; Lin X.; Lechuga M.J.; Raymond E. |
臺大學術典藏 |
2021-09-01T01:53:43Z |
Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trial
|
ANN-LII CHENG; Kang Y.-K.; Lin D.-Y.; Park J.-W.; Kudo M.; Qin S.; Chung H.-C.; Song X.; Xu J.; Poggi G.; Omata M.; Lowenthal S.P.; Lanzalone S.; Yang L.; Lechuga M.J.; Raymond E. |
臺大學術典藏 |
2020-12-02T02:33:14Z |
Final results of the large-scale multinational trial PROFILE 1005: Efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer
|
Blackhall F.; Ross Camidge D.; Shaw A.T.; Soria J.-C.; Solomon B.J.; Mok T.; Hirsh V.; J?Nne P.A.; Shi Y.; Pan-Chyr Yang; De Pas T.; Hida T.; De Castro Carpe?O J.; Lanzalone S.; Polli A.; Iyer S.; Reisman A.; Wilner K.D.; Kim D.-W.; Blackhall F.; PAN-CHYR YANG et al. |
國立臺灣大學 |
2012 |
UPDATED RESULTS OF A GLOBAL PHASE II STUDY WITH CRIZOTINIB IN ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
|
Kim, D.; Ahn, M.; Yang, P.; Liu, X.; De Pas, T.; Crino, L.; Lanzalone, S.; Polli, A.; Shaw, A. |
顯示項目 1-6 / 6 (共1頁) 1 每頁顯示[10|25|50]項目
|